These results not only expand the current understanding of MLH1-deficient colorectal cancer but also highlight the translational potential of targeting mitochondrial metabolism alongside immune checkpoint pathways as a combinatorial therapeutic strategy. This evidence concerns the gene MLH1 and colorectal cancer.